irectors and executive officers of Regeneration Technologies and their
ownership of Regeneration Technologies common stock is set forth in the
proxy statement, dated March 30, 2007, for Regeneration Technologies'
annual meeting of stockholders, as filed with the S.E.C. on a Schedule 14A.
Information about the directors and executive officers of Tutogen and their
ownership of Tutogen common stock is set forth in the proxy statement,
dated February 5, 2007, for Tutogen's annual meeting of stockholders, as
filed with the S.E.C. on a Schedule 14A. Additional information regarding
the interests of those participants and other persons who may be deemed
participants in the merger may be obtained by reading the joint proxy
statement/prospectus regarding the proposed merger when it becomes
available. You may obtain free copies of these documents as described in
the preceding paragraph.
Financial Tables to Follow
Consolidated Statement of Income (Loss)
Years Ended September 30, 2007, 2006 and 2005
(In Thousands, Except for Share and Per Share Data)
2007 2006 2005
Revenue $53,819 $37,947 $31,860
Cost of revenue 23,009 16,336 20,129
Gross profit 30,810 21,611 11,731
Operating Expenses
General and administrative 9,277 7,803 5,790
Distribution and marketing 15,795 12,261 11,509
Research and development 2,203 1,834 1,659
Total Operating Expenses 27,275 21,898 18,958
Operating income (loss) 3,535 (287) (7,227)
Foreign exchange loss (118) (311) (173)
Interest and
'/>"/>
SOURCE Tutogen Medical, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 Related biology technology :1.
Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference2.
Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products3.
Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products4.
Tutogen Medical, Inc. to Report Fourth Quarter and Fiscal Year 2007 Financial Results5.
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound6.
QMed, Inc. Reports July Medicare SNP Enrollments7.
Phlo Affiliate Reports Expanded Coverage to Oregon Border8.
Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results9.
Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 200710.
Carrington Reports Second Quarter 2007 Results11.
Avitar Reports Third Quarter Financial Results for Fiscal 2007